Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Sales (2016 - 2025)

Historic Return on Sales for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 1.13%.

  • Ultragenyx Pharmaceutical's Return on Sales fell 1700.0% to 1.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.92%, marking a year-over-year increase of 1500.0%. This contributed to the annual value of 1.02% for FY2024, which is 3800.0% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Return on Sales is 1.13%, which was down 1700.0% from 0.69% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Return on Sales' 5-year high stood at 0.69% during Q2 2025, with a 5-year trough of 2.7% in Q3 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Return on Sales value was 1.41% (recorded in 2021), while the average stood at 1.36%.
  • Data for Ultragenyx Pharmaceutical's Return on Sales shows a peak YoY increase of 19100bps (in 2021) and a maximum YoY decrease of -18200bps (in 2021) over the last 5 years.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Return on Sales (Quarter) stood at 1.5% in 2021, then dropped by 0bps to 1.5% in 2022, then surged by 36bps to 0.97% in 2023, then grew by 15bps to 0.82% in 2024, then plummeted by -38bps to 1.13% in 2025.
  • Its Return on Sales was 1.13% in Q3 2025, compared to 0.69% in Q2 2025 and 1.08% in Q1 2025.